Shenzhen - Delayed Quote CNY

Yili Chuanning Biotechnology Co.,Ltd. (301301.SZ)

12.92
-0.28
(-2.12%)
As of 2:30:34 PM GMT+8. Market Open.
Loading Chart for 301301.SZ
  • Previous Close 13.20
  • Open 14.50
  • Bid 12.91 x --
  • Ask 12.92 x --
  • Day's Range 12.86 - 13.28
  • 52 Week Range 10.41 - 16.58
  • Volume 45,929,905
  • Avg. Volume 32,129,228
  • Market Cap (intraday) 28.775B
  • Beta (5Y Monthly) 0.19
  • PE Ratio (TTM) 21.53
  • EPS (TTM) 0.60
  • Earnings Date --
  • Forward Dividend & Yield 0.22 (1.70%)
  • Ex-Dividend Date May 22, 2024
  • 1y Target Est 15.00

Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid. Yili Chuanning Biotechnology Co.,Ltd. was incorporated in 2010 and is based in Yining, China.

www.klcnsw.com

3,184

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 301301.SZ

View More

Performance Overview: 301301.SZ

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

301301.SZ
8.94%
SSE Composite Index (000001.SS)
0.88%

1-Year Return

301301.SZ
11.81%
SSE Composite Index (000001.SS)
7.05%

3-Year Return

301301.SZ
17.78%
SSE Composite Index (000001.SS)
7.45%

5-Year Return

301301.SZ
17.78%
SSE Composite Index (000001.SS)
20.16%

Compare To: 301301.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 301301.SZ

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    29.40B

  • Enterprise Value

    29.66B

  • Trailing P/E

    22.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.31

  • Price/Book (mrq)

    3.59

  • Enterprise Value/Revenue

    5.36

  • Enterprise Value/EBITDA

    18.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    24.15%

  • Return on Assets (ttm)

    9.70%

  • Return on Equity (ttm)

    17.19%

  • Revenue (ttm)

    5.53B

  • Net Income Avi to Common (ttm)

    1.34B

  • Diluted EPS (ttm)

    0.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14B

  • Total Debt/Equity (mrq)

    17.14%

  • Levered Free Cash Flow (ttm)

    1.56B

Research Analysis: 301301.SZ

View More

Company Insights: 301301.SZ

Research Reports: 301301.SZ

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.